Impact of Anti-angiogenic Agents on Chemotherapy Efficacy in Patients With Metastatic Colorectal Cancer: Second-line FOLFIRI Plus Bevacizumab or Aflibercept

被引：3

作者：

Yamada, Yunami ^{[1
]}

Matsuhashi, Nobuhisa ^{[2
]}

Fujii, Hironori ^{[1
]}

Makiyama, Akitaka ^{[2
]}

Iihara, Hirotoshi ^{[1
]}

Takahashi, Takao ^{[2
]}

Watanabe, Daichi ^{[1
]}

Kiyama, Shigeru ^{[2
]}

Kobayashi, Ryo ^{[1
]}

Suzuki, Akio ^{[1
]}

Yoshida, Kazuhiro ^{[2
]}

机构：

[1] Gifu Univ Hosp, Dept Pharm, 1-1 Yanagido, Gifu 5011194, Japan

[2] Gifu Univ, Grad Sch Med, Dept Surg Oncol, Gifu, Japan

来源：

ANTICANCER RESEARCH | 2021年 / 41卷 / 01期

关键词：

Aflibercept; Bevacizumab; unresectable metastatic colorectal cancer; overall survival; tumor response; 1ST-LINE THERAPY; SOLID TUMORS; OXALIPLATIN; COMBINATION; FLUOROURACIL; LEUCOVORIN; IRINOTECAN; PLACEBO;

D O I：

10.21873/anticanres.14805

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: We compared the efficacy and safety of second-line FOLFIRI with bevacizumab (Bmab) or aflibercept (AFL) in patients with unresectable metastatic colorectal cancer (mCRC) to clarify selection criteria for anti-angiogenic agents. Patients and Methods: The subjects were patients with mCRC who received second-line FOLFIRI in combination with Bmab or AFL. The primary endpoint was median overall survival (OS). Secondary endpoints were median time to treatment failure (77'F), overall response rate (ORR) and incidence of adverse events. Results: Data from 26 patients in the Bmab group and 19 in the AFL group were analyzed. Median OS was slightly longer in the AFL group compared to the Bmab group, whereas median TTF was similar. ORR tended to be higher in the AFL group. The incidence of >= grade 2 diarrhea and proteinuria was significantly higher in the AFL group than the Bmab group. Conclusion: In patients given combination treatment with FOLFIRI for second-line treatment of mCRC, AFL can increase response rates compared to Bmab, which may contribute to longer survival.

引用

页码：533 / 541

页数：9

共 25 条

[1] Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial [J].

Bennouna, Jaafar ;

Sastre, Javier ;

Arnold, Dirk ;

Osterlund, Pia ;

Greil, Richard ;

Van Cutsem, Eric ;

von Moos, Roger ;

Maria Vieitez, Jose ;

Bouche, Olivier ;

Borg, Christophe ;

Steffens, Claus-Christoph ;

Alonso-Orduna, Vicente ;

Schlichting, Christoph ;

Reyes-Rivera, Irmarie ;

Bendahmane, Belguendouz ;

Andre, Thierry ;

Kubicka, Stefan .

LANCET ONCOLOGY, 2013, 14 (01) :29-37

[2]

Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]

[3] Differential Antitumor Activity of Aflibercept and Bevacizumab in Patient-Derived Xenograft Models of Colorectal Cancer [J].

Chiron, Marielle ;

Bagley, Rebecca G. ;

Pollard, Jack ;

Mankoo, Parminder K. ;

Henry, Christophe ;

Vincent, Loic ;

Geslin, Catherine ;

Baltes, Nina ;

Bergstrom, Donald A. .

MOLECULAR CANCER THERAPEUTICS, 2014, 13 (06) :1636-1644

[4] Early tumor shrinkage after first-line medical treatment of metastatic colorectal cancer: a meta-analysis [J].

Colloca, Giuseppe A. ;

Venturino, Antonella ;

Guarneri, Domenico .

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (03) :231-240

[5] Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer [J].

Denda, Tadamichi ;

Sakai, Daisuke ;

Hamaguchi, Tetsuya ;

Sugimoto, Naotoshi ;

Ura, Takashi ;

Yamazaki, Kentaro ;

Fujii, Hirofumi ;

Kajiwara, Takeshi ;

Nakajima, Takako Eguchi ;

Takahashi, Shin ;

Otsu, Satoshi ;

Komatsu, Yoshito ;

Nagashima, Fumio ;

Moriwaki, Toshikazu ;

Esaki, Taito ;

Sato, Takeo ;

Itabashi, Michio ;

Oki, Eiji ;

Sasaki, Toru ;

Sunaga, Yoshinori ;

Ziti-Ljajic, Samira ;

Brillac, Claire ;

Yoshino, Takayuki .

CANCER SCIENCE, 2019, 110 (03) :1032-1043

[6] Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer [J].

Devaux, Madeline ;

Gerard, Laura ;

Richard, Corentin ;

Bengrine-Lefevre, Leila ;

Vincent, Julie ;

Schmitt, Antonin ;

Ghiringhelli, Francois .

WORLD JOURNAL OF CLINICAL ONCOLOGY, 2019, 10 (02) :75-85

[7] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[8] Clinical pharmacology of intravitreal anti-VEGF drugs [J].

Fogli, Stefano ;

Del Re, Marzia ;

Rofi, Eleonora ;

Posarelli, Chiara ;

Figus, Michele ;

Danesi, Romano .

EYE, 2018, 32 (06) :1010-1020

[9] Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients [J].

Ghiringhelli, Francois ;

Vincent, Julie ;

Beltjens, Francoise ;

Bengrine, Leila ;

Ladoire, Sylvain .

INVESTIGATIONAL NEW DRUGS, 2015, 33 (06) :1263-1266

[10] Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200 [J].

Giantonio, Bruce J. ;

Catalano, Paul J. ;

Meropol, Neal J. ;

O'Dwyer, Peter J. ;

Mitchell, Edith P. ;

Alberts, Steven R. ;

Schwartz, Michael A. ;

Benson, Al B., III .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) :1539-1544

← 1 2 3 →